Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600581 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
A Phase 2 study of Sarcopenic Obesity and Muscle Performance, sponsored by Immunis.
- Active
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 4
- Study locations
NCT06600581: Active Phase 2 study of Sarcopenic Obesity and Muscle Performance, sponsored by Immunis.
NCT06600581 is a Phase 2 study of Sarcopenic Obesity and Muscle Performance that is active but no longer recruiting, run by Immunis. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06600581, a Phase 2 study of Sarcopenic Obesity and Muscle Performance, is active but no longer recruiting, sponsored by Immunis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 4
- Study locations
Study Summary
Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
Primary Outcome
Safety and tolerability of the IP will be measured by regular monitoring of study subjects' vital signs, blood and urine testing, symptom assessments, physical examinations and physical function testing to identify changes that may be related to the IP. Monitoring begins before treatment and continues for three months following the completion of treatment.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL IMM01-STEM
- BIOLOGICAL IMM01-STEM alternating with placebo (saline)
Study Locations (4)
California
- National Institute of Clinical Research (NICR) - Garden Grove
- National Institute of Clinical Research (NICR) - Pomona
Kansas
- Johnson Country Clinical Trials (JCCT) - Lenexa
- Tekton Research - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
What the registry record for NCT06600581 still lists
NCT06600581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Sarcopenic Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06600581 reports a single indexed study location in California, Kansas.
Frequently Asked Questions
What is clinical trial NCT06600581 about?
NCT06600581 is a clinical study titled "Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness". Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
What is the current status of trial NCT06600581?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2024-12-19. Estimated completion is 2026-12-15.
What conditions does trial NCT06600581 study?
This clinical trial studies the following conditions: Sarcopenic Obesity, Muscle Performance.
What interventions are being tested in trial NCT06600581?
The interventions under investigation include: Placebo (OTHER), IMM01-STEM (BIOLOGICAL), IMM01-STEM alternating with placebo (saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06600581?
This trial is sponsored by Immunis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600581 being conducted?
This trial has 4 study locations across California, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcopenic Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06600581's enrollment target sits among peer trials
55 1153rd of 2000 higher than 841 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI